Neurothera Labs Inc.
NTLX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | ||
|---|---|---|---|---|---|
| Revenue | -26.65% | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -26.65% | -- | -- | -- | |
| Cost of Revenue | -63.36% | -- | -- | -- | |
| Gross Profit | 23.47% | -- | -- | -- | |
| SG&A Expenses | 113.13% | -- | -- | -- | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 25.39% | -- | -- | -- | |
| Operating Income | -39.40% | -- | -- | -- | |
| Income Before Tax | -33.53% | -- | -- | -- | |
| Income Tax Expenses | 280.00% | -- | -- | -- | |
| Earnings from Continuing Operations | -33.79% | -- | -- | -- | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -75.79% | -- | -- | -- | |
| Net Income | -73.45% | -- | -- | -- | |
| EBIT | -39.40% | -- | -- | -- | |
| EBITDA | -45.89% | -- | -- | -- | |
| EPS Basic | -44.93% | -- | -- | -- | |
| Normalized Basic EPS | -233.23% | -- | -- | -- | |
| EPS Diluted | -44.93% | -- | -- | -- | |
| Normalized Diluted EPS | -233.23% | -- | -- | -- | |
| Average Basic Shares Outstanding | 43.46% | -- | -- | -- | |
| Average Diluted Shares Outstanding | 76.79% | -- | -- | -- | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |